

Release to the Australian Securities Exchange

XTEK signs exclusive distribution agreement for rapid biosecurity screening for the SARS-CoV-2 virus

Tuesday 30 March 2021: XTEK Limited (ASX:XTE) ("XTEK" or the "Company") is pleased to announce it has signed an exclusive distribution agreement with KeyOptions Pty Ltd ("KeyOptions") for the sale and support of Virolens® in Australia, New Zealand and the Pacific independent states.

Key highlights

- XTEK has signed an exclusive distribution agreement with KeyOptions for the sale and support of Virolens
- The initial term of the agreement is two years
- Virolens screens for SARS-CoV-2, that causes the disease called COVID-19, in approximately 20-30 seconds
- The Virolens product has been accepted by the UK MHRA for registration as an in vitro diagnostic (IVD) Medical Devices Directive 98/79/EC; and an application has been lodged with the TGA for registration as a Class 1 IVD medical device

XTEK has signed an agreement with KeyOptions, a master agent for Virolens. The agreement appoints XTEK as the exclusive distributor in Australia, New Zealand, the Pacific independent states and specific named accounts outside the Australian region. The initial term of the agreement is two years, with year-to-year automatic renewal thereafter. Exclusivity is subject to minimum sales requirements in year 1. Subject to regulatory and other relevant approvals, XTEK will supply Virolens products, consumables, training and maintenance to end users, third party service providers and others who will carry out testing at sites.

Virolens is designed to screen for SARS-CoV-2 in approximately 20-30 seconds (98.1% sensitivity [true positive], 99.7% specificity [true negative] based on results of an internal in-vitro validation study - 184 samples). Virolens is made by a UK start-up, i-Abra, and manufactured by a listed company in the UK.

The Virolens product has been accepted by the UK Medical and Healthcare product Regulatory Agency (MHRA) and an application has been lodged by KeyOptions with the Therapeutic Goods Administration (TGA) in Australia.

Revenues to XTEK from the sale of Virolens are subject to the TGA approval and are dependent on potential end customers converting expressions of interest into firm orders. There continues to be a wide range of potential commercial outcomes and hence no certainty as to the financial impact on XTEK.

Announcement authorised by the XTEK Limited Board of Directors.

Signed for and on behalf of XTEK Limited:



Lawrence A Gardiner
Company Secretary
30 March 2021

General enquiries:

Philippe Odouard, Managing Director

XTEK Limited

T: +61 2 6163 5507

E: philippe@xtek.net

Media enquiries:

Rod North, Managing Director

Bourse Communications Pty Ltd

T: +613 9510 8309 M: +61 408 670 706

E: rod@boursecommunications.com.au

About the Virolens® System

The Virolens® system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera to capture holographic images to analyse saliva samples, with the data run through a neural network computer which is trained to identify the virus from other cells, delivering an end result in around 20-30 seconds. The proof of concept demonstrated the Virolens® system had a 98.1% sensitivity and 99.7% specificity, based on the results of an internal in-vitro validation study – 184 samples. No large clinical trial has yet been completed. As the Virolens is a solution based in technology and physics rather than biology, this has helped it to be rapidly developed and rolled out. Virolens is designed by a British company i-Abra Ltd. (incorporated on 16 Aug 2004). For more information visit the websites at <https://virolens.keyoptions.com/> and <https://i-abra.com>

About KeyOptions Pty Ltd

KeyOptions Pty Ltd (incorporated on 28 Apr 1988) provides world-leading disruptive technology solutions for connected and sustainable communities. It innovates, designs and develops solutions for clients in the government, defence, security, urban, commercial and retail industries. KeyOptions helps provide meaningful metrics that have impact on companies' operations and profitability as well as keeping people safe and secure. A number of the team are ex-military and are familiar with working in complex and challenging environments and have worked on many leading-edge technology integration projects delivering innovative and transformational outcomes. KeyOptions has a global presence with offices in Melbourne, UK & Latin America with partners in USA, Europe, Middle East & Pacific / Asia Regions.

About XTEK Limited

XTEK Limited provides high-quality products to deliver tailored security solutions to the government, law enforcement, military, space and commercial sectors. XTEK is focused on developing and commercialising its proprietary technologies by leveraging its established distribution network. These technologies include XTclave™ produced ballistic products and advanced composite solutions, and XTatlas™ real time contextual video, which provide unique solutions for western military forces and other government agencies. In addition, the supply and maintenance of Small Unmanned Aerial Systems (SUAS) remains a focus for XTEK. For more information visit the XTEK website at www.xtek.net.